Transthyretin (TTR) Amyloidosis Market Research Report Information: Disease (Transthyretin (TTR) Familial Amyloid Polyneuropathy), Gender (Male & Female), Treatment (Small Molecule Treatment), & End-User (Ambulatory Surgical Center, Clinics) – Forecast Till 2030

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Transthyretin (TTR) Amyloidosis, by Disease Type

6.1 Introduction

6.2 Transthyretin (TTR) Familial Amyloid Polyneuropathy

Market Estimates & Forecast, 2020–2027

Market Estimates & Forecast, by Region/Country, 2020–2027

6.3 Transthyretin (TTR) Familial Amyloid Cardiomyopathy

Market Estimates & Forecast, 2020–2027

Market Estimates & Forecast, by Region/Country, 2020–2027

6.4 Others

Market Estimates & Forecast, 2020–2027

Market Estimates & Forecast, by Region/Country, 2020–2027

7. Global Transthyretin (TTR) Amyloidosis, by Treatment

7.1 Introduction

7.2 Small molecules treatment

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.2.1Tafamidis

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.2.2 Diflunisal

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.3 RNAi therapy

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.4 Organ Transplantation

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

7.5 Others

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

8. Global Transthyretin (TTR) Amyloidosis, by Gender

8.1 Introduction

8.2 Male

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

8.3 Female

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

9. Global Transthyretin (TTR) Amyloidosis, by End-User

9.1 Introduction

9.2 Ambulatory Surgical Centers

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

9.3 Hospitals & Clinics

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

9.4 Others

• Market Estimates & Forecast, 2020–2027

• Market Estimates & Forecast, by Region/Country, 2020–2027

10 Global Transthyretin (TTR) Amyloidosis, by Region

10.1 Introduction

10.2 Americas

• Market Estimates & Forecast, by Region, 2020–2027

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.2.1 North America

• Market Estimates & Forecast, by Country, 2020–2027

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.2.1.1 U.S.

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.2.1.2 Canada

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.2.2 South America

• Market Estimates & Forecast, by Treatment, 2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3 Europe

• Market Estimates & Forecast, by Region, 2020–2027

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1 Western Europe

• Market Estimates & Forecast, by Country, 2020–2027

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease Type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.1 Germany

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.2 France

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.3 U.K.

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender , 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.4 Italy

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender , 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.5 Spain

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.1.6 Rest of Western Europe

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.3.2 Eastern Europe

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4 Asia Pacific

• Market Estimates & Forecast, by Country, 2020–2027

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.1 Japan

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.2 China

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.3 India

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.4 Australia

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.5 Republic of Korea

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.4.6 Rest of Asia Pacific

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5 The Middle East & Africa

• Market Estimates & Forecast, by Region, 2020–2027

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.1 United Arab Emirates

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.2 Saudi Arabia

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.3 Oman

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.4 Kuwait

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.5 Qatar

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

10.5.6 Rest of the Middle East & Africa

• Market Estimates & Forecast, by Treatment,2020–2027

• Market Estimates & Forecast, by Disease type, 2020–2027

• Market Estimates & Forecast, by Gender, 2020–2027

• Market Estimates & Forecast, by End-User, 2020–2027

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 Pfizer

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Merck

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Alnylam Pharmaceuticals

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Ionis Pharmaceuticals Inc.

12.4.1 Company Overview

12.4.2 Product Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Corino Therapeutics Inc

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Proclara Bioscience

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Arcturus Therapeutics

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of the Pharmaceutical Industry

14 Appendix

LIST OF TABLES

Table 1 Transthyretin (TTR) (TTR) amyloidosis Industry Synopsis, 2020–2027

Table 2 Global Transthyretin (TTR) Amyloidosis Estimates and Forecast, 2020–2027, (USD Million)

Table 3 Global Transthyretin (TTR) Amyloidosis, by Region, 2020–2027, (USD Million)

Table 4 Global Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 5 Global Transthyretin (TTR) Amyloidosis, by Treatment, 2020–2027, (USD Million)

Table 6 Global Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 7 Global Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 8 North America Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 9 North America Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 10 North America Transthyretin (TTR) Amyloidosis, by Treatment, 2020–2027, (USD Million)

Table 11 North America Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 12 US Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 13 US Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 14 US Transthyretin (TTR) Amyloidosis, by Treatment, 2020–2027, (USD Million)

Table 15 US Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 16 Canada Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 17 Canada Transthyretin (TTR) Amyloidosis, by Treatment, 2020–2027, (USD Million)

Table 18 Canada Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 19 Canada Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 20 South America Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 21 South America Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 22 South America Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 23 Europe Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 24 Europe Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 25 Europe Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 26 Western Europe Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 27 Western Europe Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 28 Western Europe Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 29 Eastern Europe Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 30 Eastern Europe Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 31 Eastern Europe Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 32 Asia Pacific Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 33 Asia Pacific Transthyretin (TTR) Amyloidosis, by Gender, 2020–2027, (USD Million)

Table 34 Asia Pacific Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

Table 35 Middle East & Africa Transthyretin (TTR) Amyloidosis, by Disease type, 2020–2027, (USD Million)

Table 36 Middle East & Africa Transthyretin (TTR) Amyloidosis, by diagnoses, 2020–2027, (USD Million)

Table 37 Middle East & Africa Transthyretin (TTR) Amyloidosis, by End-Users, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Transthyretin (TTR) Amyloidosis

Figure 3 Segmentation Market Dynamics for Transthyretin (TTR) Amyloidosis

Figure 4 Global Transthyretin (TTR) Amyloidosis Share, by Disease type 2020

Figure 5 Global Transthyretin (TTR) Amyloidosis Share, by Treatment 2020

Figure 6 Global Transthyretin (TTR) Amyloidosis Share, by End-Users, 2020

Figure 7 Global Transthyretin (TTR) Amyloidosis Share, by Region, 2020

Figure 8 North America Transthyretin (TTR) Amyloidosis Share, by Country, 2020

Figure 9 Europe Transthyretin (TTR) Amyloidosis Share, by Country, 2020

Figure 10 Asia Pacific Transthyretin (TTR) Amyloidosis Share, by Country, 2020

Figure 11 Middle East & Africa Transthyretin (TTR) Amyloidosis Share, by Country, 2020

Figure 12 Global Transthyretin (TTR) Amyloidosis: Company Share Analysis, 2020 (%)

Figure 13 Arcturus Therapeutics: Key Financials

Figure 14 Arcturus Therapeutics: Segmental Revenue

Figure 15 Arcturus Therapeutics: Geographical Revenue

Figure 16 Merck. Key Financials

Figure 17 Merck: Segmental Revenue

Figure 18 Merck: Geographical Revenue

Figure 19 Alnylam Pharmaceuticals: Key Financials

Figure 20 Alnylam Pharmaceuticals: Segmental Revenue

Figure 21 Alnylam Pharmaceuticals: Geographical Revenue

Figure 22 Ionis Pharmaceuticals Inc.: Key Financials

Figure 23 Ionis Pharmaceuticals Inc.: Segmental Revenue

Figure 24 Ionis Pharmaceuticals Inc.: Geographical Revenue

Figure 25 Corino Therapeutics Inc: Key Financials

Figure 26 Corino Therapeutics Inc: Segmental Revenue

Figure 27 Corino Therapeutics Inc.: Geographical Revenue

Figure 28 Merck. Key Financials

Figure 29 Merck. Segmental Revenue

Figure 30 Merck. Geographical Revenue

Figure 31 Pfizer Key Financials

Figure 32 Pfizer Segmental Revenue

Figure 33 Pfizer Geographical Revenue